Pioglitazone Induces Dysplastic Urothelial Changes in Urinary Bladder of Experimental Diabetes

OBJECTIVES: Pioglitazone (PIO) is a widely prescribed oral antidiabetic drug that has concerns regarding a potential risk of developing carcinoma of the urinary bladder. The objective of the current study was to assess this potential risk. MATERIALS AND METHODS: The potential risk of PIO-induced uri...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdel-Hamid, Ahmed A. M., Firgany, Alaa El-Din L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10153741/
https://www.ncbi.nlm.nih.gov/pubmed/37144164
http://dx.doi.org/10.4103/jmau.jmau_34_21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10153741/
https://www.ncbi.nlm.nih.gov/pubmed/37144164
http://dx.doi.org/10.4103/jmau.jmau_34_21

Ejemplares similares